Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SPARSENTAN
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
- A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
- Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Clinical trials list
click for details